Skip to main content
NYSE:UPC

Universe Pharmaceuticals Competitors

$3.09
-0.14 (-4.33 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.01
$3.40
50-Day Range
$3.06
$5.65
52-Week Range
$3.01
$11.99
Volume253,890 shs
Average Volume3.85 million shs
Market Capitalization$67.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Universe Pharmaceuticals (NYSE:UPC) Vs. KLDO, UBX, VINC, RPHM, ANVS, and DBTX

Should you be buying UPC stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Universe Pharmaceuticals, including Kaleido Biosciences (KLDO), Unity Biotechnology (UBX), Vincerx Pharma (VINC), Reneo Pharmaceuticals (RPHM), Annovis Bio (ANVS), and Decibel Therapeutics (DBTX).

Kaleido Biosciences (NASDAQ:KLDO) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Institutional and Insider Ownership

79.9% of Kaleido Biosciences shares are owned by institutional investors. 10.0% of Kaleido Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Kaleido Biosciences and Universe Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaleido Biosciences11402.50
Universe Pharmaceuticals0000N/A

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 207.56%. Given Kaleido Biosciences' higher possible upside, analysts clearly believe Kaleido Biosciences is more favorable than Universe Pharmaceuticals.

Earnings & Valuation

This table compares Kaleido Biosciences and Universe Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido BiosciencesN/AN/AN/A($3.36)-1.73
Universe PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Kaleido Biosciences and Universe Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaleido BiosciencesN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/A

Summary

Kaleido Biosciences beats Universe Pharmaceuticals on 4 of the 4 factors compared between the two stocks.

Universe Pharmaceuticals (NYSE:UPC) and Unity Biotechnology (NASDAQ:UBX) are both small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Institutional & Insider Ownership

37.2% of Unity Biotechnology shares are owned by institutional investors. 37.3% of Unity Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Universe Pharmaceuticals and Unity Biotechnology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Universe Pharmaceuticals0000N/A
Unity Biotechnology14001.80

Unity Biotechnology has a consensus price target of $4.80, suggesting a potential upside of 12.68%. Given Unity Biotechnology's higher possible upside, analysts clearly believe Unity Biotechnology is more favorable than Universe Pharmaceuticals.

Valuation & Earnings

This table compares Universe Pharmaceuticals and Unity Biotechnology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe PharmaceuticalsN/AN/AN/AN/AN/A
Unity BiotechnologyN/AN/AN/A($1.88)-2.27

Profitability

This table compares Universe Pharmaceuticals and Unity Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Universe PharmaceuticalsN/AN/AN/A
Unity BiotechnologyN/AN/AN/A

Summary

Unity Biotechnology beats Universe Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

Universe Pharmaceuticals (NYSE:UPC) and Vincerx Pharma (NASDAQ:VINC) are both small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Valuation & Earnings

This table compares Universe Pharmaceuticals and Vincerx Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe PharmaceuticalsN/AN/AN/AN/AN/A
Vincerx PharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for Universe Pharmaceuticals and Vincerx Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Universe Pharmaceuticals0000N/A
Vincerx Pharma00103.00

Given Vincerx Pharma's higher possible upside, analysts clearly believe Vincerx Pharma is more favorable than Universe Pharmaceuticals.

Profitability

This table compares Universe Pharmaceuticals and Vincerx Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Universe PharmaceuticalsN/AN/AN/A
Vincerx PharmaN/AN/AN/A

Summary

Vincerx Pharma beats Universe Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Universe Pharmaceuticals (NYSE:UPC) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Universe Pharmaceuticals and Reneo Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe PharmaceuticalsN/AN/AN/AN/AN/A
Reneo PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Universe Pharmaceuticals and Reneo Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Universe Pharmaceuticals0000N/A
Reneo Pharmaceuticals00303.00

Reneo Pharmaceuticals has a consensus target price of $31.3333, indicating a potential upside of 291.18%. Given Reneo Pharmaceuticals' higher possible upside, analysts clearly believe Reneo Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Profitability

This table compares Universe Pharmaceuticals and Reneo Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Universe PharmaceuticalsN/AN/AN/A
Reneo PharmaceuticalsN/AN/AN/A

Summary

Reneo Pharmaceuticals beats Universe Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Universe Pharmaceuticals (NYSE:UPC) and Annovis Bio (NYSE:ANVS) are both small-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Universe Pharmaceuticals and Annovis Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe PharmaceuticalsN/AN/AN/AN/AN/A
Annovis BioN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Universe Pharmaceuticals and Annovis Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Universe Pharmaceuticals0000N/A
Annovis Bio00103.00

Annovis Bio has a consensus target price of $45.00, indicating a potential upside of 93.30%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than Universe Pharmaceuticals.

Profitability

This table compares Universe Pharmaceuticals and Annovis Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Universe PharmaceuticalsN/AN/AN/A
Annovis BioN/AN/AN/A

Summary

Annovis Bio beats Universe Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Decibel Therapeutics (NASDAQ:DBTX) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Earnings and Valuation

This table compares Decibel Therapeutics and Universe Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel TherapeuticsN/AN/AN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Decibel Therapeutics and Universe Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Decibel Therapeutics00503.00
Universe Pharmaceuticals0000N/A

Decibel Therapeutics presently has a consensus price target of $28.80, indicating a potential upside of 350.70%. Given Decibel Therapeutics' higher possible upside, analysts plainly believe Decibel Therapeutics is more favorable than Universe Pharmaceuticals.

Profitability

This table compares Decibel Therapeutics and Universe Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Decibel TherapeuticsN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/A

Summary

Decibel Therapeutics beats Universe Pharmaceuticals on 2 of the 2 factors compared between the two stocks.


Universe Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$5.82-9.3%$247.46 millionN/A-2.30
Unity Biotechnology logo
UBX
Unity Biotechnology
1.3$4.26-3.5%$233.40 millionN/A-2.27Earnings Announcement
VINC
Vincerx Pharma
1.0$16.34-1.0%$228.50 millionN/A0.00
RPHM
Reneo Pharmaceuticals
2.0$8.01-39.2%$193.93 millionN/A0.00Quiet Period Expiration
Annovis Bio logo
ANVS
Annovis Bio
1.7$23.28-7.3%$161.73 millionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Up
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.1$6.39-11.1%$159.12 millionN/A0.00Analyst Downgrade
News Coverage
LBPH
Longboard Pharmaceuticals
1.9$8.76-5.9%$148.19 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.50-9.3%$143.77 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.00-8.7%$106.89 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$5.30-5.7%$101.76 millionN/A0.00News Coverage
Gap Down
LGVN
Longeveron
0.0$5.20-1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52-3.8%$68.47 millionN/A0.00
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.90-9.0%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11-8.7%$44.64 millionN/A0.00Gap Up
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$7.66-20.0%$39.63 millionN/A0.00Analyst Downgrade
VIRI
Virios Therapeutics
1.3$4.71-2.1%$39.23 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
1.7$16.59-3.4%$38.77 millionN/A0.00Analyst Report
News Coverage
Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.20-1.6%$37.69 millionN/A0.00Gap Down
VYNT
Vyant Bio
0.0$2.88-2.8%$31.70 millionN/A0.00Gap Up
MYMD
MyMD Pharmaceuticals
0.0$3.64-2.5%$30.31 millionN/A0.00Upcoming Earnings
VLON
Vallon Pharmaceuticals
0.0$3.71-1.1%$25.27 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$3.85-2.6%$19.04 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.08-4.2%$17.91 millionN/A0.00
PALI
Palisade Bio
0.0$4.60-14.1%$13.26 millionN/A0.00Upcoming Earnings
High Trading Volume
Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.33-7.3%$0.00N/A0.00Earnings Announcement
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06-0.0%$0.00N/A0.00Gap Down
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00
SCPS
Scopus BioPharma
1.4$5.17-0.6%$0.00N/A0.00
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.